COVID-19: Antikörperkombination AZD7442 robust wirksam bei Hochrisikopatienten

被引：0
|
作者：
Redaktion Facharztmagazine
机构：
[1] Springer Medizin,
来源：
MMW - Fortschritte der Medizin | 2022年 / 164卷 / 1期
关键词：
D O I：
10.1007/s15006-022-0686-5
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：71 / 71
相关论文
共 50 条
  • [1] Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19
    Levin, Myron J.
    Ustianowski, Andrew
    De Wit, Stephane
    Launay, Odile
    Avila, Miles
    Templeton, Alison
    Yuan, Yuan
    Seegobin, Seth
    Ellery, Adam
    Levinson, Dennis J.
    Ambery, Philip
    Arends, Rosalinda H.
    Beavon, Rohini
    Dey, Kanika
    Garbes, Pedro
    Kelly, Elizabeth J.
    Koh, Gavin C. K. W.
    Near, Karen A.
    Padilla, Kelly W.
    Psachoulia, Konstantina
    Sharbaugh, Audrey
    Streicher, Katie
    Pangalos, Menelas N.
    Esser, Mark T.
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (23): : 2188 - 2200
  • [2] Accelerated cell culture process development and characterization for cilgavimab/tixagevimab (AZD7442) for the prevention and treatment of COVID-19
    Handlogten, Michael W.
    Bosley, Stefanie
    Dunn, Sarah
    Zhu, Jie
    Lee-O'Brien, Allison
    Li, Lina
    Therres, Jamy
    Chakrabarti, Lina
    Khanal, Bijay
    Mowery, Rachel
    Arumugam, Subhashini
    Klover, Judith
    Taleb, Mohammed
    Reier, Jason
    Hatton, Diane
    Schmelzer, Albert
    BIOTECHNOLOGY AND BIOENGINEERING, 2023,
  • [3] AZD7442 utilization for Pre-Exposure Prophylaxis Against COVID-19 in a French Early Access Program
    Artaud, C.
    Majed, L.
    Fabry-Vendrand, C.
    Taylor, S.
    Ferreira, C.
    Dube, S.
    Thabut, G.
    Suau, D.
    Lahouegue, A.
    EUROPEAN JOURNAL OF PUBLIC HEALTH, 2023, 33
  • [4] Covid-19: AstraZeneca says its antibody drug AZD7442 is effective for preventing and reducing severe illness
    Mahase, Elisabeth
    BMJ-BRITISH MEDICAL JOURNAL, 2021, 375 : n2860
  • [5] COST-EFFECTIVENESS OF AZD7442 (TIXAGEVIMAB AND CILGAVIMAB) FOR PRE-EXPOSURE PROPHYLAXIS AGAINST COVID-19 IN THE IMMUNOCOMPROMISED POPULATION
    Sutton, K.
    Miller, P.
    Branscombe, N.
    Mittal, M.
    Browne, C.
    Arnetorp, S.
    Henry, T.
    Breslin, K.
    Bungey, G.
    Quint, J.
    Montgomery, H.
    VALUE IN HEALTH, 2022, 25 (12) : S168 - S168
  • [6] Tixagevimab/cilgavimab (AZD7442/Evusheld) prevent from COVID19 in patients with hematologic malignancies under active chemotherapy
    Lee, Yoo Jin
    Kim, Hyun-Ki
    Kim, Youjin
    Park, Sang Hyuk
    Lim, Ji-Hun
    Jung, Jiwon
    Choi, Yun-suk
    Jo, Jae-Cheol
    ANNALS OF HEMATOLOGY, 2024, 103 (07) : 2533 - 2539
  • [7] Analysis of SARS-CoV-2 Emergent Variants Following AZD7442 (Tixagevimab/Cilgavimab) for Early Outpatient Treatment of COVID-19 (TACKLE Trial)
    Kijak, Gustavo H.
    Ahani, Bahar
    Arbetter, Douglas
    Chuecos, Fernando
    Gopalakrishnan, Vancheswaran
    Beloor, Jagadish
    Brady, Tyler
    Nguyen, Amy
    Roe, Tiffany L.
    Schuko, Nicolette
    Zhang, Tianhui
    Hobbs, F. D. Richard
    Padilla, Francisco
    Kelly, Elizabeth J.
    Montgomery, Hugh
    Streicher, Katie
    INFECTIOUS DISEASES AND THERAPY, 2023, 12 (12) : 2691 - 2707
  • [8] Outpatient Treatment with AZD7442 (Tixagevimab/Cilgavimab) Prevented COVID-19 Hospitalizations over 6 Months and Reduced Symptom Progression in the TACKLE Randomized Trial
    Hobbs, F. D. Richard
    Montgomery, Hugh
    Padilla, Francisco
    Simon-Campos, Jesus Abraham
    Kim, Kenneth
    Arbetter, Douglas
    Padilla, Kelly W.
    Reddy, Venkatesh Pilla
    Seegobin, Seth
    Streicher, Katie
    Templeton, Alison
    Viani, Rolando M.
    Johnsson, Eva
    Koh, Gavin C. K. W.
    Esser, Mark T.
    INFECTIOUS DISEASES AND THERAPY, 2023, 12 (09) : 2269 - 2287
  • [9] Analysis of SARS-CoV-2 Emergent Variants Following AZD7442 (Tixagevimab/Cilgavimab) for Early Outpatient Treatment of COVID-19 (TACKLE Trial)
    Gustavo H. Kijak
    Bahar Ahani
    Douglas Arbetter
    Fernando Chuecos
    Vancheswaran Gopalakrishnan
    Jagadish Beloor
    Tyler Brady
    Amy Nguyen
    Tiffany L. Roe
    Nicolette Schuko
    Tianhui Zhang
    F. D. Richard Hobbs
    Francisco Padilla
    Elizabeth J. Kelly
    Hugh Montgomery
    Katie Streicher
    Infectious Diseases and Therapy, 2023, 12 : 2691 - 2707
  • [10] Efficacy, Safety, and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Prevention of Symptomatic COVID-19: 15-Month Final Analysis of the PROVENT and STORM CHASER Trials
    Levin, Myron J.
    Ustianowski, Andrew
    De Wit, Stephane
    Beavon, Rohini
    Thissen, Jesse
    Seegobin, Seth
    Dey, Kanika
    Near, Karen A.
    Streicher, Katie
    Kiazand, Alexandre
    Esser, Mark T.
    INFECTIOUS DISEASES AND THERAPY, 2024, 13 (06) : 1253 - 1268
12345